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ABSTRACT
Precision oncology requires sensitive and specific clinical biomarkers. 
Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal 
adenocarcinoma (PDA) but lacks sensitivity and specificity. Nearly all PDAs harbor 
somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) KRAS as an 
alternative disease biomarker, however, variable clinical performance has limited its 
clinical utility. We applied an ultrasensitive, PCR mutation enrichment, next generation 
sequencing ctDNA KRAS assay in a large cohort of patients with unresectable 
PDA (N = 189) recruited to the BIOPAC study between 2008–2015. Baseline and 
longitudinal serum CA19-9 and plasma ctDNA KRAS were correlated with time to 
progression (TTP) and overall survival (OS). Baseline ctDNA KRAS detection rate was 
93.7% (86.4% in patients with non-elevated CA19-9). ctDNA KRAS and CA19-9 were 
positively correlated yet independently associated with TTP and OS (ctDNA KRAS  
p = 0.0018 and 0.0014; CA19-9 p = 0.0294 and 0.0007, respectively). A generated 
model quantitating longitudinal ctDNA KRAS correctly assessed greater than 80% of 
patient responses. Quantitative detection of KRAS ctDNA is an informative prognostic 
biomarker, complementary to CA19-9 in patients with unresectable PDA. Longitudinal 
ctDNA KRAS may inform therapeutic decision making and provides a kinetically 
dynamic and quantitative metric of patient response.
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INTRODUCTION
Many of the most recent advances in oncology 
have been related to the field of precision medicine. For 
example, the introduction of targeted therapies in lung, 
colon, and breast cancer have contributed to a significant 
increase in overall survival (OS) related to these diseases 
[1–3]. Patients with pancreatic ductal adenocarcinoma 
(PDA) have not seen the same benefit of these precision 
oncology advances [4, 5]. The 5-year survival rate of 
patients with locally advanced or metastatic PDA has only 
seen modest increases over the last several decades, from 
5% to more recent estimates of 8–9% [4–6].
Identification and utilization of reliable and 
informative biomarkers will play a pivotal role in precision 
oncology, not only for triaging patients to appropriate 
molecularly guided therapies, but also to inform 
therapeutic decision making [7]. In PDA, carbohydrate 
antigen 19-9 (CA19-9) has long been the biomarker of 
choice, has a sensitivity and specificity of 79–81% and 
82–90% respectively, and is recommended for use by 
the National Comprehensive Cancer Network (NCCN) 
(v.02.2016) [8–11]. In patients with resectable disease, 
which accounts for less than 20% of those diagnosed 
[12], pre-operative serum CA19-9 levels, and serial serum 
CA19-9 measurements before and after surgery can be 
prognostic, and post-operative serum CA19-9 levels can 
help determine adjuvant therapy course [13]. In patients 
with advanced disease, the ability of serum CA19-9 to 
help determine treatment benefit during chemotherapy has 
generated conflicting results [14–20]. 
Currently, there are no clinically useful 
biomarkers established for treatment selection in 
patients with unresectable PDA. Daily clinical decision-
making is based on imaging techniques and CA19-9. 
However, these tools are not always accurate in patient 
identification or outcome prediction. Serum CA19-9 has 
its limitations, primarily because 10–15% of patients 
do not express Lewis Body antigen, meaning that 
their CA19-9 levels are not informative [21]. In these 
patients, there is no validated biomarker for determining 
prognosis at time of diagnosis or for use in monitoring 
of therapeutic response. Additionally, CA19-9 can be 
elevated in non-neoplastic, inflammatory conditions, like 
pancreatitis, as well as due to biologic conditions like 
stent blockage [21, 22].
Detection of circulating tumor DNA (ctDNA) has 
rapidly emerged as an alternative to tissue biopsy in 
identifying the presence or absence of clinically actionable 
genomic alterations within a tumor [23–25]. Longitudinal 
monitoring of ctDNA has been shown to serve as a 
biomarker for predicting patient outcome by quantitating 
dynamic changes in ctDNA mutation load in response to 
a therapeutic intervention. Multiple studies have reported 
correlation between dynamic changes in the levels of a 
specific ctDNA mutation with radiographic response 
[26–28]. However, these studies have examined individual 
patients (i.e., anecdotal data) and not the development 
and testing of a clinical tool within a patient population 
that could be used to monitor and predict response. PDA 
presents a unique opportunity for molecular diagnosis 
and monitoring given that over 90–95% of patients 
with PDA harbor somatic KRAS G12/G13 mutations 
as the primary driver of mutagenesis [29–32]. Given 
this fact, measurement of ctDNA for detection and 
quantitative monitoring of KRAS mutations may offer a 
complementary diagnostic and prognostic biomarker to 
CA19-9. Researchers have attempted to harness advancing 
ctDNA technologies to understand the clinical utility of 
ctDNA KRAS in patients with PDA as a diagnostic and 
prognostic biomarker, biomarker for drug response, and 
molecular monitoring tool. Previous studies have reported 
low ctDNA KRAS detection rates ranging from 27% to 
71%, hampering the advancement of ctDNA KRAS as a 
reliable clinical tool [23, 27, 33–38].
Here we report on the application of an ultrasensitive 
ctDNA KRAS assay used in patients with unresectable 
PDA, and its use as a prognostic biomarker independent 
and complementary to CA19-9. We also introduce novel 
work utilizing dynamic changes in ctDNA KRAS mutation 
load from serial measurements as an assessment of 
therapeutic response.
RESULTS
In this prospective, retrospective analysis of CA19-9 
and ctDNA KRAS in patients with newly diagnosed 
American Joint Committee on Cancer (AJCC) stage III or 
stage IV PDA, 189 patients met inclusion criteria and had 
baseline samples that passed preliminary quality control 
analysis (Table 1). The majority of patients (78.8%) were 
diagnosed with Stage IV disease. In this cohort, all patients 
were treated with chemotherapy with the primary first 
line chemotherapy being gemcitabine (66.7%) which is 
consistent with primary therapy for this patient population 
during the recruitment period. Median number of ctDNA 
KRAS timepoints per patient was 3 (interquartile range 
(IQR) 2–4) and median number of CA19-9 timepoints per 
patient was 8 (IQR 4–16).
Baseline statistics and primary variates
Plasma ctDNA KRAS mutation detection rate in this 
189 patient cohort was 93.7% (N = 177; 95% confidence 
interval (CI) 89.2%–96.7%) (Table 2). The most frequently 
detected KRAS mutations were G12D (40.7%) and G12V 
(31.1%) (Table 1), which is consistent with the most 
common mutations identified through somatic testing 
of pancreatic adenocarcinoma tumors [39]. The median 
number of ctDNA KRAS copies detected at baseline was 
335.4 copies per 105 Genome Equivalents (GEq) (IQR of 
54–2,214 copies per 105 GEq). For CA19-9, 167 patients 
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had baseline levels above 37 units per milliliter (U/mL) and 
were considered elevated (88.4%; 95% CI 82.9%–92.6%) 
(Table 2). The median U/mL was 1,890 (IQR 412 – 12, 160 
U/mL). ctDNA KRAS was detectable at baseline for 19 of 
22 patients that had non-elevated CA19-9 levels (86.4%; 
95% CI 65.1%–97.1%) (Table 2). The addition of baseline 
ctDNA KRAS to this cohort significantly increased patient 
identification ( p = 0.0020). For baseline positive samples, 
there was a significant, positive relationship between CA19-9 
and ctDNA KRAS (Figure 1) (Pearson’s Correlation 
Coefficient r = 0.295; p = 0.0002; Spearman’s rank 
correlation r = 0.312; p < 0.0001).
The median number of baseline plasma ctDNA 
KRAS copies was higher in patients with stage IV versus 
stage III PDA (608.2 versus 56.0 copies per 105 GEq; 
p < 0.0001) (Figure 2A). This was also observed in 
baseline serum CA19-9 (3,230 versus 540 U/mL; 
p < 0.0001) (Figure 2B). When the quantitative baseline 
values of ctDNA KRAS and CA19-9 were plotted versus 
disease stage, there was a notable bi-modal distribution for 
ctDNA KRAS that was not observed for CA19-9 (Figure 3). 
The resulting natural cut-point was approximately 250 
ctDNA KRAS copies per 105 GEq (Figure 3A). This natural 
cut-point was utilized in subsequent calculations to categorize 
the number of ctDNA KRAS copies into “High” and 
“Low” bins. For serum CA19-9, the median (1,890 U/mL) 
was utilized in subsequent calculations for a similar 
categorization (Figure 3B).
Association with time to disease progression
One-hundred and thirteen patients achieved 
disease progression (PD) during first line of palliative 
chemotherapy (59.8%; 95% CI 52.4%–66.8%). Primary 
reasons for not reaching PD were death and loss to 
follow-up (missing CT evaluation). Median time to 
progression (TTP) during first line of chemotherapy was 
85 days and did not differ significantly based on disease 
stage (stage IV: 84 days versus stage III: 151 days; p = 
0.1094) (Figure 4A). However, there was a difference 
in TTP for stage IV versus III disease that trended 
towards significance (Hazard Ratio (HR) = 1.26, 95% 
CI 1.00–1.59, p = 0.0504).  Irrespective of disease stage, 
baseline ctDNA KRAS above the natural bimodal cutpoint 
Table 1: Demographics for 189 patients
Characteristic Median (Q1–Q3)
Age, years 67 (60–72)
Number (%)
Gender
 Male
 Female
95 (50.3)
94 (49.7)
ECOG Performance Status
 0
 1
 2
70 (37.4)
99 (52.4)
20 (10.6)
Stage
 III
 IV
40 (21.2)
149 (78.8)
Chemotherapy type
 Gemcitabine
 FOLFIRINOX
126 (66.7)
63 (33.3)
ctDNA KRAS mutation detected at baseline1
 G12A
 G12C
 G12D
 G12R
 G12S
 G12V
 G13D
4 (2.3)
18 (10.2)
72 (40.7)
22 (12.4)
4 (2.3)
55 (31.1)
2 (1.1)
1Available for 177 patients.
Q - quartiles. 
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Table 2: Detection concordance between ctDNA KRAS and serum CA19-9 
CA19-9
Detected Not Detected Total
ctDNA KRAS
Detected 158 19 177
Not Detected 9 3 12
Total 167 22 189
ctDNA – circulating tumor DNA.
Figure 1: Significant positive relationship between baseline CA19-9 and ctDNA KRAS for positive samples (N = 158). 
Pearson’s correlation coefficient r = 0.295; p = 0.0002. Spearman’s Rank Correlation r = 0.312; p < 0.0001.
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Figure 2: Boxplots of ctDNA KRAS (A) and CA19-9 (B) for baseline detected samples.
Figure 3: (A) Density plot of ctDNA KRAS copies per 105 GEq in 177 patients with detectable baseline results stratified by stage. Dotted 
vertical line denotes the bimodal cutpoint of approximately 250 copies per 105 GEq. (B) Density plot of CA19-9 U/mL for 167 patients with 
detected baseline samples stratified by stage. Dotted vertical line denotes the median cutpoint of approximately 1,890 units per milliliter.
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was associated with PD (HR 1.29; 95% CI 1.06–1.57, 
p = 0.0105), as was CA19-9 above its respective median 
(HR 1.25; 95% CI 1.02–1.53, p = 0.0354).
In a univariate analysis, baseline ctDNA 
KRAS was associated with TTP (HR = 1.42; 95% CI 
1.12–1.76, p = 0.0013). In a multivariate regression 
analysis, utilizing baseline CA19-9, and baseline ctDNA 
KRAS as continuous variables, along with the co-variates 
of interest, stage, gender (sex), and baseline European 
Cooperative Oncology Group (ECOG) performance 
score, ctDNA KRAS remained highly significant for 
TTP (HR = 1.45; 95% CI 1.15–1.83, p = 0.0017), while 
baseline CA19-9 was less significant (HR = 1.27; 95% CI 
1.03–1.58, p = 0.0284) along with sex (HR = 0.79; 95% CI 
0.63–0.99, p = 0.0400) (Table 3).
When analyzing the categorical cutpoints and TTP, 
there was not a significant difference in the median TTP 
in patients with stage IV disease based on their baseline 
CA19-9 level ( p = 0.2550; Figure 5A). In contrast, those 
with a diagnosis of stage IV disease had a borderline 
significant association based on their ctDNA KRAS level 
( p = 0.0554; Figure 5B). The number of patients with 
stage III disease and high baseline CA19-9 (N = 4) was too 
few for calculations, as was the number of patients with 
stage III disease and high baseline ctDNA KRAS (N = 3).
Association with overall survival
OS was calculated for 183 patients for a median OS 
of 188 days (IQR of 96–326 days). Patients with stage 
IV disease had a significantly shorter OS than those with 
stage III disease (stage IV: 164 days versus stage III: 
313 days; p = 0.0005) (Figure 4B). In addition to this, 
a baseline ctDNA KRAS above the natural bimodal cut-
point (Hazard ratio (HR) = 1.36; 95% CI 1.16–1.59, p = 
0.0001), a baseline CA19-9 value above the median (1,890 
U/mL) (HR = 1.34; 95% CI 1.15–1.57, p = 0.0003), and 
disease stage (stage III versus stage IV) (HR = 1.34; 
95% CI 1.12–1.61, p = 0.0014) were each significantly 
associated with OS.
Univariate analysis demonstrated that baseline 
plasma ctDNA KRAS as a continuous variable (HR = 1.42; 
95% CI 1.19–1.69, p < 0.0001) and baseline serum 
CA19-9 as a continuous variable (HR = 1.36; 95% CI 
1.17–1.59, p < 0.0001) were each directly associated with 
OS significantly. In a multivariate regression analysis, 
categorical ctDNA KRAS and CA19-9 along with the 
other co-variates (stage, gender (sex), baseline ECOG 
performance status) were utilized to determine their 
respective associations with OS. Both ctDNA KRAS and 
CA19-9 when analyzed with the co-variates of interest 
were associated with OS (ctDNA KRAS: HR = 1.45; 95% 
CI 1.17–1.80, p = 0.0007; CA19-9: HR = 1.31; 95% CI 
1.11–1.53, p = 0.0014). Other significant variates included 
gender and baseline ECOG performance status (Table 3). 
Patients with stage III disease and low baseline 
CA19-9 (N = 28) had a longer OS than those with stage 
IV disease, regardless of which categorical CA19-9 status 
( p < 0.0001 for CA19-9 high, p = 0.0333 for CA19-9 
low; Figure 6A). Patients with stage IV disease and a high 
baseline CA19-9 level (N = 74) had a significantly shorter 
OS than those with stage IV disease and a low baseline 
Figure 4: Boxplots of time to disease progression in days (A) and overall survival in days (B) for baseline samples stratified by stage.
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CA19-9 (N = 52; p = 0.0009) (Figure 6A). The number 
of patients with stage III disease and high baseline CA19-
9 was too few for calculations (N = 7). Similarly, for 
baseline ctDNA KRAS, patients with stage III disease and 
low baseline ctDNA KRAS levels (N = 26) had a longer 
OS than patients with stage IV disease, regardless of 
baseline ctDNA KRAS level ( p = 0.0170 and < 0.0001; 
Figure 6B). Patients with stage IV disease and a high 
baseline ctDNA KRAS (N = 85) had a significantly shorter 
OS than those with stage IV disease and low baseline 
ctDNA KRAS levels (N = 55; p = 0.0425) (Figure 6B). 
The number of patients with stage III disease and high 
Table 3: Multivariate regression analysis: prognostic performance of continuous variable ctDNA KRAS and CA19-9
Variate HR (95% CI) Coefficientp
Overall Survival*  
 CA19-9 1.30 (1.11–1.53) 0.0014
 ctDNA KRAS 1.45 (1.17–1.80) 0.0007
 Sex 0.79 (0.67–0.93) 0.0060
Age 1.03 (1.01–1.05) 0.0068
Performance Score 1 and 2 0.80 (0.67–0.96) 0.0148
Time to Progression*  
 CA19-9 1.27 (1.03–1.58) 0.0284
ctDNA KRAS 1.45 (1.15–1.83) 0.0017
Sex 0.79 (0.63–0.99) 0.0400
*Overall model fit was assessed by Likelihood and Wald scores. Corresponding p-values of the model were < 0.0001 
indicating a good fit.
Figure 5: Kaplan Meier curves demonstrating the patient time to progression (TTP) by stage and categorical baseline CA19-9 
(A) and categorical baseline ctDNA KRAS status (B). High/low CA19-9 status was based on the median in this cohort (1,890 
U/mL) while high/low ctDNA KRAS status was based on the bimodal cutpoint of 250 copies per 105 Genome Equivalents.  Patients with 
high baseline values of ctDNA KRAS had significantly shorter TTP than those with low baseline values ( p = 0.0358) which was not 
appreciated in high/low CA19-9 status ( p = 0.1237). The number of patients with Stage III disease and high baseline CA19-9 was too few 
for calculation, as was the number of patients with Stage III disease and high baseline ctDNA KRAS. 
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baseline ctDNA KRAS was too few for calculation (N = 6), 
as was the number of patients with Stage III disease and 
high baseline CA19-9 (N = 7).
Association with performance status
Association of OS with the patient’s pre-treatment 
ECOG performance status was examined with baseline 
high and low ctDNA KRAS and CA19-9 levels. In patients 
with a performance status of 0, there was a statistically 
significant difference in OS between those patients with 
high versus low baseline CA19-9 levels ( p = 0.0024). This 
also held true in patients with a performance status of 1 
( p = 0.0121) (Figure 7A). The differences in OS were also 
significant for those with a performance status of 0 and high 
versus low baseline ctDNA KRAS ( p = 0.0053) as well as a 
performance status of 1 ( p = 0.0102) (Figure 7B). 
Plasma ctDNA KRAS as a response biomarker
In a subset of patients, details about investigator 
assessed progression were available in addition to CT scan 
response by RECIST1.1, and ctDNA KRAS and CA19-
9 data (N = 88 of 113 patients who reached PD on first 
line therapy). Most patients had an investigator assessed 
response that was confirmed by RECIST 1.1 criteria 
(N = 62 of 88; 70%). To determine whether dynamic 
changes in longitudinal ctDNA KRAS levels were 
consistent with RECIST 1.1 assessment, patients in 
which there was a plasma ctDNA KRAS within 2 weeks 
of a RECIST 1.1 assessment were examined. 51.6% of 
these patients (N = 32) had a ctDNA KRAS collection 
within 2 weeks of a RECIST 1.1 assessment, and dynamic 
longitudinal changes in mutation load trended consistent 
with RECIST 1.1 assessment in 23 patients (71.9%). In the 
remaining 26 patients where the investigator assessment 
of response differed from RECIST 1.1, 20 patients had a 
ctDNA KRAS longitudinal timepoint within 2 weeks of 
a RECIST 1.1 assessment. We observed that longitudinal 
monitoring of changes in ctDNA KRAS mutational burden 
trended consistent with RECIST 1.1 response in nearly 
half of these patients (N = 9 of 20; Figure 8).
These observations were further explored and 
formalized with predictive modeling (Figure 9). Of the 
dataset, there were 59 timepoints (matched baseline and 
longitudinal timepoint) from 46 unique patients that met 
criteria for predictive modeling (one matched timepoint 
(N = 37), two matched timepoints (N = 6), three matched 
timepoints (N = 2) and four matched timepoints (N = 1). 
Four of the 59 matched timepoints were “undetermined” as 
they had a baseline ctDNA KRAS GEq that was less than θ. 
For the remaining 55 samples, utilizing the quantitative 
Figure 6: Kaplan Meier curves demonstrating the overall survival (OS) by stage and categorical baseline CA19-9 (A) and categorical 
baseline ctDNA KRAS status (B). High/low CA19-9 status was based on the median in this cohort (1,890 U/mL) while high/low ctDNA 
KRAS status was based on the bimodal cutpoint of 250 copies per 105 Genome Equivalents. Patients with high baseline values had 
significantly shorter OS than those with low baseline values. The number of patients with Stage III disease and high baseline CA19-9 was 
too few for calculation, as was the number of patients with Stage III disease and high baseline ctDNA KRAS. 
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baseline ctDNA KRAS level and the longitudinal 
quantitative ctDNA KRAS level that was within 7 days 
of a verified RECIST 1.1 timepoint, the model correctly 
predicted the RECIST 1.1 results (PD versus SD+) in 
81.8% of matched timepoints (N = 45 of 55; 95% CI 
69.7%–90.9%) (Figure 10). Four of the 10 samples with 
discrepant calls had an associated longitudinal timepoint 
that was “not detected” for ctDNA KRAS, therefore the 
model predicted a response of “SD+” while the RECIST 
1.1 response was PD.  In the remaining six discrepant 
matched samples the model predicted a response of SD+, 
but actual response was PD. In one matched sample 
ctDNA KRAS value was borderline as the longitudinal 
timepoint was just below the threshold (Figure 11) and in 
two matched samples the ctDNA KRAS longitudinal trend 
that was mirrored by CA19-9 (Figure 11). 
DISCUSSION
We report on the utilization of a novel mutant 
allele enrichment ctDNA assay in patients with advanced 
PDA yielding a circulating tumor DNA (ctDNA) KRAS 
baseline detection rate of 93.7% (95% CI 89.2%–96.7%), 
outperforming the detection rate of prior reported assays 
[23, 27, 33–38]. The percentage of individuals without 
an informative biomarker was reduced from 11.6% when 
utilizing CA19-9 alone (22 of 189 patients), to 1.6% when 
utilizing both serum CA19-9 and plasma ctDNA KRAS (3 
of 189 patients). Utilization of CA19-9 and ctDNA KRAS 
in this cohort increased the yield of positively identified 
patients by 10.1% and resulted in a positive biomarker 
result in 186 of 189 patients. ctDNA KRAS and CA19-9 
were significantly positively correlated, demonstrating 
good performance of ctDNA KRAS alongside the currently 
accepted standard of care biomarker for PDA. 
In univariate analysis, both baseline CA19-9 and 
ctDNA KRAS were associated with overall survival (OS) 
which was expected given the known positive correlation 
between the two variates. In multivariate analysis both 
CA19-9 and ctDNA KRAS were significantly associated 
with OS, indicating that these two biomarkers capture 
unique, but complementary prognostic information. The 
multivariate analysis suggests that assessment of ctDNA 
KRAS and CA19-9 levels could be used jointly to achieve 
greater prognostic certainty within the clinical setting.
Baseline ctDNA KRAS was associated with time to 
progression (TTP). In a multivariate analysis with CA19-
9 and the additional co-variates (stage, gender, baseline 
ECOG performance status), ctDNA KRAS remains highly 
significant while CA19-9 was less significant. 
We observed a natural bimodal distribution 
of baseline quantitative plasma ctDNA KRAS copy 
number when analyzed versus PDA disease stage. Upon 
exploration of this bimodal distribution and natural 
cutpoint, it was confirmed that there are significant 
differences in outcome (OS, TTP) between these two 
patient populations, irrespective of stage of disease. 
Figure 7: Kaplan Meier curves demonstrating the overall survival based on categorical CA19-9 (high/low) and pretreatment ECOG 
performance score (A) and similarly, the overall survival based categorical ctDNA KRAS (high/low) and pretreatment ECOG performance 
score (B).
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Figure 8: Representative longitudinal plots of patients who had a different investigator assessed response as compared 
to the confirmatory RECIST 1.1 criteria. Green squares represent longitudinal CA19-9 collection timepoints, while purple circles 
represent longitudinal ctDNA KRAS collection timepoints. The CT scan RECIST 1.1 assessment is represented by diamonds on the X-axis. 
CT scans are truncated to include only those that were within 2 weeks of a ctDNA KRAS collection. 
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However, when ctDNA KRAS was examined within 
predefined stage III or stage IV disease, individuals 
with high versus low baseline ctDNA KRAS copies 
also had a significantly different OS and TTP.  These 
two observations indicate that assessment of plasma 
ctDNA KRAS levels for an individual patient may 
give greater clarity of prognosis than disease stage 
alone and underscores the potential clinical impact of 
ctDNA KRAS, a molecular biomarker, to further sub-
classify prognosis beyond the current methodologies. 
Patients with PDA and poorer performance status and 
low baseline ctDNA KRAS levels had a longer OS than 
those patients with a better performance status and high 
baseline ctDNA KRAS levels. 
Assessment of response to chemotherapy is 
challenging in patients with advanced PDA, as evidenced 
Figure 9: Predictive response model logic.
Figure 10: Representative longitudinal plots of patients in whom the ctDNA KRAS predictive model correctly assessed 
the RECIST 1.1 response. The CT scan RECIST 1.1 assessment is represented by diamonds on the X-axis. CT scans are truncated to 
include only those that were within 7 days of a ctDNA KRAS collection. 
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by the cohort of patients where in 30% of cases the 
investigator assessed response differed from response as 
confirmed by RECIST 1.1 criteria. In PDA, specifically, 
given the lethality of the cancer, there is the strong desire 
for the ability to rapidly ascertain response and inform the 
decision of whether to continue an effective therapeutic 
regimen or discontinue an ineffective one [40]. 
The utilization of serum CA19-9 has been explored 
as a potential biomarker of response, but with conflicting 
results [14, 41, 42]. A study of more than 200 patients 
with metastatic and locally advanced PDA concluded that 
changes in CA19-9 levels should not be used to make 
decisions about discontinuing or continuing therapies 
given the lack of significant positive predictive value.  The 
authors suggest that a more rigorous analysis, limiting the 
time collection timepoints to within the first two cycles of 
chemotherapy could be clinically meaningful in treatment 
decision making [20]. 
Since the first report in 1948 by Mandel and 
Metais, describing the presence of cell-free nucleic acid 
in human blood, ctDNA and its clinical utility have been 
of clinical interest [43–45]. Assessment of ctDNA, termed 
as “liquid biopsy”, can provide complementary dynamic 
information, which can aid in clinical decision making 
[24]. Somatic KRAS mutations have been reported to be 
present in greater than 90–95% of PDA cases assessed 
by tumor tissue analysis suggesting a potential biomarker 
in detecting and monitoring disease progression [29–32]. 
Several studies have been published demonstrating the 
presence of ctDNA in plasma in patients with PDA with 
varying sensitivity [23, 27, 33–37, 46–51]. Yamada et al. 
reported that high plasma ctDNA KRAS was positively 
correlated with stage and that persistent post-treatment 
detectable ctDNA KRAS mutations was associated with 
poorer prognosis [46]. Recently, Kinugasa et al. utilized 
a droplet digital PCR ctDNA technology and identified 
ctDNA KRAS mutations in 62.6% of patients with PDA 
(stages II, III and IV). Patients with detectable ctDNA 
KRAS mutations had significantly shorter survival than 
patients without detectable mutations [52]. Pietrasz et al. 
reported that 41.3% of patients with advanced PDA had 
detectable ctDNA KRAS mutation by NGS and droplet-
based dPCR in microfluidics with a high concordance 
between the two technics [38].
The high prevalence of somatic KRAS mutations 
in PDA provides an opportunity to have an informative, 
specific biomarker of response that may aid in assessment 
of response, identifying patients who are not likely to 
benefit from additional cytotoxic chemotherapy. In a novel 
predictive modeling algorithm, examining the quantitative 
change between ctDNA KRAS mutation load at baseline 
(pre-treatment) and at subsequent CT scan correctly 
predicted the RECIST 1.1 assessment in approximately 
82% of matched timepoints. This analysis was restricted 
to timepoints collected while on first line therapy, and 
those timepoints collected within 7 days of a RECIST 
1.1 assessment. The ability of longitudinal monitoring to 
correctly assess the current disease state would provide 
clinicians with a rapid, non-invasive assessment of 
response that could be repeated frequently. Future analysis 
Figure 11: Discrepant predictive modeling plots. Patient A had decreasing CA19-9 and ctDNA KRAS levels as compared to 
baseline, but a RECIST 1.1 assessment of progressive disease (PD) (A). Patient B had increasing CA19-9 and ctDNA KRAS as compared to 
baseline, but the difference between the baseline and longitudinal timepoints did not meet threshold for a PD call (B). In Patient C, there was 
a predicted response of stable disease response, and the longitudinal ctDNA KRAS was just below our threshold, thus this is a borderline 
case (C).
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will expand this modeling in a larger cohort of patients 
with PDA and with more structured collection timepoints 
and intervals. We observed that longitudinal monitoring of 
changes in ctDNA KRAS trended consistent with RECIST 
1.1 response in nearly half of the patients. It would also 
be interesting in future studies to evaluate the correlation 
between ctDNA KRAS and tumor load or shrinkage, as 
well as whether the depth of decrease of KRAS ctDNA 
from baseline could be predictive for survival.
The current study has several strengths. First, 
the study population was treated and followed within a 
single hospital system, allowing accurate clinical metric 
follow-up. Second, the Danish universal health care 
system allowed for detailed tracking of death dates for 
the patients. Third, this is one of the largest, if not the 
largest study of the application of ctDNA in patients with 
unresectable PDA. 
However, the study is not without its limitations. 
First, matched tumor tissue KRAS analysis was not 
available for this cohort. It is widely accepted that more 
than 90–95%, of PDAs harbor somatic KRAS G12/G13 
mutations. We relied on this background knowledge, 
along with the mutation distribution within the cohort 
that was consistent with what was expected, to estimate 
that the ultrasensitive ctDNA KRAS assay detected almost 
all samples correctly, however “tissue truth” was not 
available. Second, this analysis was retrospectively applied 
to prospectively collected samples. While the BIOPAC 
study design outlined the sample collection timepoints, 
these were not uniformly applied. This impacted the 
number of plasma ctDNA timepoints available within a 
RECIST 1.1-assessed CT scans. Future prospectively 
designed studies will have more rigorous enforcement of 
study sample collection timepoints and intervals. 
In conclusion, plasma ctDNA KRAS was detected 
in 93.7% of patients with stage III/IV PDA. The addition 
of plasma ctDNA KRAS to serum CA19-9 at baseline 
significantly increased patient identification. High baseline 
ctDNA KRAS mutation levels were significantly associated 
with OS and TTP in both univariate and multivariate 
models and were more significantly associated with 
prognosis than CA19-9. Longitudinal monitoring with 
ctDNA KRAS as a response biomarker successfully 
predicted response in over 80% of patients with PDA. The 
utilization of this ultrasensitive ctDNA KRAS assay not 
only provides an informative prognostic biomarker, but 
may also aid in clinical decision making at diagnosis and 
during treatment.
MATERIALS AND METHODS
Patients
Patients diagnosed and histologically verified 
with AJCC Stage III or Stage IV unresectable PDA 
between July 2008 and August 2015 at Herlev and 
Gentofte Hospital were eligible for the Danish BIOPAC 
(BIOmarkers in Pancreatic Cancer) Study and were 
prospectively enrolled [53]. The study is ongoing and 
approved by the Regional Ethics Committee (VEK ref. 
KA-20060113) and the Danish Data Protection Agency 
(j.nr. 2006-41-6848 and HGH-2015-027, I-Suite nr: 
03960). Informed consent for research use was obtained 
from all patients at the enrolling institution (Herlev and 
Gentofte Hospital, Copenhagen University Hospital, 
Denmark) before prospective plasma banking.
Patients were qualified for inclusion if they had a 
diagnosis of PDA, confirmed with CT scan and histology/
cytology and were of age 18 years or older at the time 
of diagnosis. Patients were treatment naïve at the time of 
enrollment and were treated with first line gemcitabine or 
fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin 
(FOLFIRINOX). During the study period, 241 patients 
were recruited to the study,  52 of whom were excluded 
for the following reasons: no baseline (pre-treatment) 
sample received (N = 10), no baseline (pre-treatment) CT 
scan (N = 11), data was from second line of chemotherapy 
(N = 2), patient had resectable disease (N = 2), patient 
was diagnosed with non-pancreas cancer (N = 2), patient 
was treated with radiation (N = 1), and ctDNA assay failed 
(N = 24) leaving 189 patients for analysis (Table 1). 
During treatment CT evaluation was missed in 76 patients 
due to cancer related death or rapid clinical deterioration. 
In some cases the data collection intervals were irregular 
due to different schedules of chemotherapy (Gemcitabine 
3 weeks cycle vs. FOLFIRINOX 2 weeks cycle), 
accelerated sample collection because of accelerated CT 
scan or missing samples. Last follow-up was August 2016.
Sample collection and processing
Baseline and longitudinal plasma samples were 
collected on all enrolled patients when possible. 
Study design outlined plasma collection timepoints as 
baseline (pre-treatment, prior to initiation of first line of 
chemotherapy), before administration of the second cycle 
of first line of chemotherapy, and thereafter with every CT 
scan. Actual collection time-points varied. Biobanking 
strategy in all enrolled patients was designed with the 
same standard operating procedures for the acquisition, 
handling and storage of blood samples. Plasma samples 
were collected in sodium citrate tubes and centrifuged 
within ½–2 hours (2330 g for 10 min at 4°C), and stored 
at –80°C with temperature alarm. 1.2–2 mL of plasma 
ctDNA was isolated using the QIAamp Circulating 
Nucleic Acid kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. 
Clinical data collection
Medical records and outcome data of all included 
patients were collected and reviewed retrospectively. 
Changes in tumor burden on the consecutive scans were 
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assessed according to the RECIST 1.1 by an independent 
radiologist, blinded to all clinical data and ctDNA KRAS 
information. In 30% of cases the investigator assessed 
response differed from response as confirmed by RECIST 
1.1 criteria. One-hundred and thirteen patients achieved 
disease progression as assessed by RECIST criteria. Thus, 
appearance of undoubtedly new lesions was classified as 
progressive disease (PD). We followed RECIST guidelines 
in case of a new lesion was equivocal. If repeated scans 
confirmed definitely a new lesion, then progression date 
was stated using the initial scan.  
Plasma ctDNA KRAS analysis
Quantitative analysis of the seven most common 
mutations in KRAS exon 2, codons 12 and 13 (G12A, 
G12C, G12D, G12R, G12S, G12V, G13D) was performed 
using a mutation-enrichment polymerase chain reaction 
(PCR) coupled with next generation sequencing (NGS) 
utilizing an ultra-short footprint PCR assay (gene specific 
footprint 31 bp, with overall amplicon length of 75 bp) 
to amplify highly degraded ctDNA KRAS fragments [54]. 
A proprietary pipeline processed the FASTQ files 
from the Illumina’s MiSeq Sequencing Platform with 
algorithms that were validated with a sensitivity of 96.0% 
(95% CI of 86.3%–99.5%) and specificity of 97.9% (95% 
CI of 88.7%–99.9%) with samples obtained from healthy 
volunteers, patients with wild-type KRAS G12/G13 
cancer and patients with mutant KRAS G12/G13 cancer. 
Given that detectable KRAS G12/G13 mutation levels 
were identified, the pipeline then accurately quantifies 
the mutational load using a corresponding reference set 
of standard samples that are processed on the same run. 
Final mutation copy numbers were scaled to 105 Genome 
Equivalents (GEq, refers to amount of DNA in a single cell) 
[54].  The concordance was 94% between KRAS G12/G13 
mutations in plasma cell-free DNA and FFPE tumor 
tissue [54]. 
Serum CA19-9 analysis
Pretreatment and longitudinal serum CA 19-9 
concentration was analyzed using the Immulite 2000 
GI-MA (Siemens, Catalogue Number L2KG12) assay, 
a solid-phase, two-site sequential chemiluminescent 
immunometric assay. The upper normal limit for serum 
CA 19.9 was 37 U/mL, as this is the reference range for 
CA19-9.
Statistical analysis
The results of this project are reported in accordance 
with the REMARK (Reporting recommendations for 
tumor marker prognostic study) guidelines [55]. Results 
were compiled for the 189 patients with available 
baseline, pre-treatment ctDNA specimens successfully 
processed through the proprietary pipeline along with 
the demographic information collected at baseline, CT 
imaging scans assessed with RECIST 1.1 criteria and 
serum CA19-9 results taken throughout treatment. At 
each timepoint, specimens with ctDNA KRAS G12/G13 
quantitative copy numbers greater than the established 
lower limit of detection were labeled as “detected”. 
At each timepoint, specimens with CA19-9 levels 
with greater than or equal to 37 U/mL were considered 
“elevated” according to the CA19-9 reference range. 
Analyzed longitudinal plasma and serum samples were 
collected after baseline, prior to the start of the second line 
of chemotherapy (when occurred) and at each RECIST 1.1 
assessed CT imaging within two weeks of collection. 
The response end points examined were overall 
survival (OS) and Time to Progression (TTP). OS 
is defined as the number of days from the start of the 
first line of chemotherapy to death. TTP is defined 
here as the number of days from the start of the first 
line of chemotherapy to PD given that progression is 
achieved prior to the start of any subsequent lines of 
chemotherapy. PD is defined using the RECIST 1.1 
criteria as have a greater than 20% increase in sum of 
the diameters of target lesions with an absolute increase 
of ≥ 5 mm [56].
DNA analyses were performed retrospectively and 
independently from the clinical data review. Predictive 
modeling was implemented in 46 patients, in which 
ctDNA KRAS level was within 7 days of a verified 
RECIST 1.1 timepoint. Statistical analysis examined 
both primary variates of interest, ctDNA KRAS copies per 
105 GEqand CA19-9 U/mL, against each other and with 
the response end points. Relationships for both response 
end points and primary variates along with co-variates 
of age, gender (sex), chemotherapy type, stage, and pre-
treatment ECOG performance status were evaluated. 
Non-significant variates were removed from consideration 
using backwards selection.
Cox proportional hazards regression models were 
used to assess the significance of the variates of interest. 
Confidence intervals were assessed and reported at 95% 
unless otherwise stated, and significance testing was two-
sided with p < 0.05 considered statistically significant. Due 
to the high skewness of the data, a log10 transformation 
was applied to both plasma ctDNA KRAS copy number 
and serum CA19-9 prior to analysis in order to preserve 
the normality assumption. The model was tested for fit 
utilizing Wald and Likelihood scores. 
Predictive model for response 
Additional analyses were performed for those 
samples with two or more plasma collection timepoints 
and RECIST 1.1 CT scan data available. Analysis was 
restricted to patients with a detectable baseline ctDNA 
KRAS result and at least one subsequent longitudinal 
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ctDNA timepoint within 7 days of a CT scan with RECIST 
1.1 assessment. RECIST 1.1 response was simplified and 
reported as PD or SD+. SD+ includes a RECIST 1.1 
assessment of stable disease, partial response, or complete 
response [56]. 
First, we assessed the longitudinal trends in 
quantitative ctDNA KRAS mutation load and correlated 
with RECIST 1.1 data and investigator assessed response. 
The trends observed between longitudinal measurements 
of ctDNA KRAS and RECIST 1.1 status were strong 
enough to be explicitly quantified and demonstrated the 
ability to identify RECIST 1.1 response by measuring 
quantitative changes in ctDNA KRAS mutation load 
as compared to baseline. Given a minimal threshold of 
ctDNA KRAS copies at baseline (annotated as θ), trends 
were analyzed over large search grids to determine the 
minimum ctDNA KRAS copies correlating with ctDNA 
KRAS response of PD (annotated as α). If a longitudinal 
measurement was less than the α minimum PD 
threshold and less than the baseline measurement plus a 
corresponding shift threshold (annotated as ϕ), the ctDNA 
KRAS response was assessed as SD+. Otherwise, the 
ctDNA KRAS response was called to be PD (Figure 5). 
All statistical analyses were carried out using R 
version 3.2.3 statistical software.
Abbreviations
BIOPAC, Biomarkers in Pancreatic Cancer; CA19-9, 
Carbohydrate Antigen 19-9; ctDNA, circulating 
tumor DNA; CI, confidence interval; GEq, Genome 
Equivalents; HR, Hazard ratio; IQR, interquartile range; 
NGS, next generation sequencing; OS, overall survival; 
p, p value; PCR, polymerase chain reaction; PD, disease 
progression; PDA, Pancreatic Ductal Adenocarcinoma; 
RECIST, Response Evaluation Criteria In Solid Tumors; 
SD, Stable disease; TTP, time to progression; U/mL, units 
per milliliter.
Author contributions
All authors contributed to study design and editing 
and review of the manuscript. JAG was responsible for 
statistical analysis. IC, VMR, JAG, MGE, and JSJ were 
responsible for compilation of data and manuscript 
writing, KLH was responsible for radiology review.
ACKNOWLEDGMENTS
The authors would like to acknowledge the patients 
and families for their participation in this research. We 
would also like to acknowledge Latifa Hassaine, Saege 
Hancock, Errin Samuelsz, Cecile Rose Vibat and Vlada 
Melnikova for their work in sequencing analysis and 
manuscript review. Many thanks to the biomedical 
laboratory scientists Charlotte Falk, Vibeke Hintze Holm, 
Dorthe Baunbjerg Nielsen and Helle Bekker Sørensen, 
Department of Oncology, Herlev & Gentofte Hospital 
for excellent technical assistance. Thanks to Dr. Stig E. 
Bojesen, Department of Clinical Biochemistry, Herlev & 
Gentofte Hospital for measurement of serum CA 19-9. We 
also thank Astrid Z. Johansen for data collection in the 
BIOPAC database.
CONFLICTS OF INTEREST
VMR, JAG and MGE are full time employees of 
Trovagene, Inc. 
EAC has received consulting fees from Qiagen 
and Guardant and research support from Ignyta, Daiichi-
Sankyo.
REFERENCES
1. Chan BA, Hughes BGM. Targeted therapy for non-small 
cell lung cancer: current standards and the promise of the 
future. Transl Lung Cancer Res. 2015; 4:36–54. https://doi.
org/10.3978/j.issn.2218-6751.2014.05.01.
2. Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, 
Costa L, Andrade S, Batel-Marques F. The benefit of 
HER2-targeted therapies on overall survival of patients 
with metastatic HER2-positive breast cancer – a systematic 
review. Breast Cancer Res. 2015; 17:140. https://doi.
org/10.1186/s13058-015-0648-2.
3. El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly 
targeted therapy for metastatic colon cancer: proven 
treatments and promising new agents. Gastrointest Cancer 
Res. 2011; 4:15–21.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, 
Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, 
Harris M, Reni M, Dowden S, et al. Increased survival in 
pancreatic cancer with nab-paclitaxel plus gemcitabine. 
N Engl J Med. 2013; 369:1691–703. https://doi.
org/10.1056/NEJMoa1304369.
5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, 
Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, 
de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-
Akouz F, et al. FOLFIRINOX versus gemcitabine for 
metastatic pancreatic cancer. N Engl J Med. 2011; 
364:1817–25. https://doi.org/10.1056/NEJMoa1011923.
6. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, 
Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, 
Mariotto A, Lewis D, Chen H, et al. SEER Cancer Statistics 
Review, 1975-2013. http://seer.cancer.gov/csr/1975_2013.
7. Carethers JM, Braun J, Sands BE. Genetics, genetic testing, 
and biomarkers of digestive diseases. Gastroenterology. 2015; 
149:1131–3. https://doi.org/10.1053/j.gastro.2015.08.049.
8. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. 
Cancer antigens 19-9 and 125 in the differential diagnosis 
Oncotarget97784www.impactjournals.com/oncotarget
of pancreatic mass lesions. Arch Surg. 2006; 141:968–973. 
https://doi.org/10.1001/archsurg.141.10.968.
9. Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, 
Zerbi A, Beretta E, Di Carlo V. Determination of CA 
19-9 antigen in serum and pancreatic juice for differential 
diagnosis of pancreatic adenocarcinoma from chronic 
pancreatitis. Gastroenterology. 1987; 92:60–7.
10. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, 
Aste H, Pugliese V. CA 19-9 and CA 50 in benign and 
malignant pancreatic and biliary diseases. Cancer. 1988; 
61:2100–8.
11. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, 
Podolsky DK. Evaluation of a serologic marker, CA19-9, 
in the diagnosis of pancreatic cancer. Ann Intern Med. 1989; 
110:704–9.
12. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. 
The Lancet. 2016; 388:73–85. https://doi.org/10.1016/
S0140-6736(16)00141-0.
13. Ballehaninna UK, Chamberlain RS. The clinical utility of 
serum CA 19-9 in the diagnosis, prognosis and management 
of pancreatic adenocarcinoma: an evidence based appraisal. 
J Gastrointest Oncol. 2011; 3:105–119.
14. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, 
Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, 
Herrmann R. CA 19-9 tumour-marker response to 
chemotherapy in patients with advanced pancreatic 
cancer enrolled in a randomised controlled trial. 
Lancet Oncol. 2008; 9:132–8. https://doi.org/10.1016/
S1470-2045(08)70001-9.
15. Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, 
Riess H. Value of carbohydrate antigen 19-9 in predicting 
response and therapy control in patients with metastatic 
pancreatic cancer undergoing first-line therapy. Front 
Oncol. 2013. https://doi.org/10.3389/fonc.2013.00155.
16. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, 
Keim V. Decrease of CA 19–9 during chemotherapy 
with gemcitabine predicts survival time in patients with 
advanced pancreatic cancer. Br J Cancer. 2000; 82:1013.
17. Kanazu M, Maruyama K, Ando M, Asami K, Ishii M, 
Uehira K, Minomo S, Matsuda Y, Kawaguchi T, 
Atagi S, Ogawa Y, Kusunoki Y, Takada M, et al. Early 
pharmacodynamic assessment using 18F-fluorodeoxyglucose 
positron-emission tomography on molecular targeted therapy 
and cytotoxic chemotherapy for clinical outcome prediction. 
Clin Lung Cancer. 2014; 15:182–7. https://doi.org/10.1016/j.
cllc.2014.01.001.
18. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, 
Tempero MA. Serum CA19-9 response as a surrogate 
for clinical outcome in patients receiving fixed-dose rate 
gemcitabine for advanced pancreatic cancer. Br J Cancer. 
2005; 93:195–9. https://doi.org/10.1038/sj.bjc.6602687.
19. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, 
Tempero MA. Serum CA19-9 decline compared to 
radiographic response as a surrogate for clinical outcomes 
in patients with metastatic pancreatic cancer receiving 
chemotherapy. Pancreas. 2008; 37:269–74.
20. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, 
Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate 
antigen 19-9 is a prognostic and predictive biomarker in 
patients with advanced pancreatic cancer who receive 
gemcitabine-containing chemotherapy: a pooled analysis 
of 6 prospective trials. Cancer. 2013; 119:285–92. https://
doi.org/10.1002/cncr.27734.
21. Tempero MA, Uchida E, Takasaki H, Burnett DA, 
Steplewski Z, Pour PM. Relationship of carbohydrate 
antigen 19-9 and Lewis antigens in pancreatic cancer. 
Cancer Res. 1987; 47:5501–3.
22. Galli C, Basso D, Plebani M. CA 19-9: handle with care. 
Clin Chem Lab Med. 2013. https://doi.org/10.1515/
cclm-2012-0744.
23. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, 
Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, 
Antonarakis ES, Azad NS, Bardelli A, et al. Detection 
of circulating tumor DNA in early- and late-stage human 
malignancies. Sci Transl Med. 2014; 6:224ra24. https://doi.
org/10.1126/scitranslmed.3007094.
24. Diaz LA, Bardelli A. Liquid biopsies: genotyping 
circulating tumor DNA. J Clin Oncol. 2014; 32:579–86. 
https://doi.org/10.1200/JCO.2012.45.2011.
25. Haber DA, Velculescu VE. Blood-based analyses of cancer: 
circulating tumor cells and circulating tumor DNA. Cancer 
Discov. 2014; 4:650–61. https://doi.org/10.1158/2159-8290.
CD-13-1014.
26. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, 
Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, 
Croucher P, Samuelsz E, Vibat CR, Guerrero S, et al. 
A highly sensitive and quantitative test platform for detection 
of NSCLC EGFR mutations in urine and plasma. J Thorac 
Oncol. 2016. https://doi.org/10.1016/j.jtho.2016.05.035.
27. Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen 
Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, 
Smaaland R. Clinical relevance of circulating KRAS 
mutated DNA in plasma from patients with advanced 
pancreatic cancer. Mol Oncol. 2016; 10:635–43. https://doi.
org/10.1016/j.molonc.2015.11.012.
28. Siravegna G, Mussolin B, Buscarino M, Corti G, 
Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, 
Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, 
et al. Clonal evolution and resistance to EGFR blockade 
in the blood of colorectal cancer patients. Nat Med. 2015; 
21:795–801. https://doi.org/10.1038/nm.3870.
29. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, 
Perucho M. Most human carcinomas of the exocrine 
pancreas contain mutant c-K-ras genes. Cell. 1988; 53: 
549–54. https://doi.org/10.1016/0092-8674(88)90571-5.
30. Hruban RH, van Mansfeld AD, Offerhaus GJ, van 
Weering DH, Allison DC, Goodman SN, Kensler TW, 
Bose KK, Cameron JL, Bos JL. K-ras oncogene activation 
Oncotarget97785www.impactjournals.com/oncotarget
in adenocarcinoma of the human pancreas. A study of 
82 carcinomas using a combination of mutant-enriched 
polymerase chain reaction analysis and allele-specific 
oligonucleotide hybridization. Am J Pathol. 1993; 
143:545–54.
31. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, 
Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MCJ, 
Robertson AJ, Fadlullah MZH, et al. Whole genomes 
redefine the mutational landscape of pancreatic cancer. 
Nature. 2015; 518:495–501. https://doi.org/10.1038/
nature14169.
32. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, 
Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, 
Choti MA, Yeo CJ, McCue P, et al. Whole-exome 
sequencing of pancreatic cancer defines genetic diversity 
and therapeutic targets. Nat Commun. 2015. https://doi.
org/10.1038/ncomms7744.
33. Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E, Solé M, 
Capellà G, Lluís F, Fernández-Cruz L, Navarro S, Farré A. 
K-ras mutations in DNA extracted from the plasma of 
patients with pancreatic carcinoma: diagnostic utility and 
prognostic significance. J Clin Oncol. 1999; 17:578–84.
34. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras 
mutational status predicts poor prognosis in unresectable 
pancreatic cancer. Eur J Surg Oncol. 2010; 36:657–62. 
https://doi.org/10.1016/j.ejso.2010.05.014.
35. Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc PH, 
Ruszniewski P, Puig PL. Differential diagnosis between 
chronic pancreatitis and pancreatic cancer: value of the 
detection of KRAS2 mutations in circulating DNA. 
Br J Cancer. 2002; 87:551–4. https://doi.org/10.1038/
sj.bjc.6600475.
36. Pishvaian MJ, Bender RJ, Matrisian LM, Rahib L, Hendifar A, 
Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, 
Mason K, Varieur K, Aberra M, et al. A pilot study 
evaluating concordance between blood-based and patient-
matched tumor molecular testing within pancreatic cancer 
patients participating in the Know Your Tumor (KYT) 
initiative. Oncotarget. 2017; 8:83446–56. https://doi.
org/10.18632/oncotarget.13225.
37. Brychta N, Krahn T, von Ahsen O. Detection of KRAS 
mutations in circulating tumor DNA by digital PCR in early 
stages of pancreatic cancer. Clin Chem. 2016. https://doi.
org/10.1373/clinchem.2016.257469.
38. Pietrasz D, Pécuchet N, Garlan F. Plasma circulating tumor 
DNA in pancreatic cancer patients is a prognostic marker. 
Clin Cancer Res. 2017. https://doi.org/10.1158/1078-0432.
CCR-16-0806.
39. Prior IA, Lewis PD, Mattos C. A comprehensive survey of 
Ras mutations in cancer. Cancer Res. 2012; 72:2457–67. 
https://doi.org/10.1158/0008-5472.CAN-11-2612.
40. Rahib L, Fleshman JM, Matrisian LM, Berlin JD. 
Evaluation of pancreatic cancer clinical trials and 
benchmarks for clinically meaningful future trials: a 
systematic review. JAMA Oncol. 2016; 2:1209. https://doi.
org/10.1001/jamaoncol.2016.0585.
41. Hammad N, Heilbrun LK, Philip PA, Shields AF, 
Zalupski MM, Venkatramanamoorthy R, El-Rayes BF. CA19-9 
as a predictor of tumor response and survival in patients with 
advanced pancreatic cancer treated with gemcitabine based 
chemotherapy. Asia Pac J Clin Oncol. 2010; 6:98–105. https://
doi.org/10.1111/j.1743-7563.2010.01290.x.
42. Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, 
Strehl J, Sauerbruch T, Schmidt-Wolf IGH. Prognostic value 
of CA 19-9 levels in patients with inoperable adenocarcinoma 
of the pancreas treated with gemcitabine. Br J Cancer. 2003; 
89:1413–7. https://doi.org/10.1038/sj.bjc.6601263.
43. Mandel P, Metais P. Les acides nucléiques du plasma 
sanguin chez l’homme. C R Seances Soc Biol Fil. 1948; 
142:241–3.
44. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA 
in the serum of cancer patients and the effect of therapy. 
Cancer Res. 1977; 37:646–50.
45. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. 
Determination of circulating DNA levels in patients with benign 
or malignant gastrointestinal disease. Cancer. 1983; 51:2116–20. 
https://doi.org/10.1002/1097-0142(19830601)51:11<2116::AID-
CNCR2820511127>3.0.CO;2-S.
46. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, 
Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, 
Sakon M, Gotoh M, Monden M. Detection of K-ras gene 
mutations in plasma DNA of patients with pancreatic 
adenocarcinoma: correlation with clinicopathological 
features. Clin Cancer Res. 1998; 4:1527–32.
47. Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, 
Alstead EM, Ballinger A, Farthing MJ, Stroun M. 
A prospective study of K-ras mutations in the plasma of 
pancreatic cancer patients. Clin Cancer Res. 1998; 4:271–5.
48. Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, 
Zurong Y, Xuezhi W. A prospective study of detection of 
pancreatic carcinoma by combined plasma K-ras mutations 
and serum CA19-9 analysis. Pancreas. 2002; 25:336–41.
49. Uemura T, Hibi K, Kaneko T, Takeda S, Inoue S, Okochi O, 
Nagasaka T, Nakao A. Detection of K-ras mutations 
in the plasma DNA of pancreatic cancer patients. 
J Gastroenterol. 2004; 39:56–60. https://doi.org/10.1007/
s00535-003-1245-1.
50. Takai E, Totoki Y, Nakamura H, Kato M, Shibata T, 
Yachida S. Clinical utility of circulating tumor DNA for 
molecular assessment and precision medicine in pancreatic 
cancer. Adv Exp Med Biol. 2016; 924:13–7. https://doi.
org/10.1007/978-3-319-42044-8_3.
51. Däbritz J, Hänfler J, Preston R, Stieler J, Oettle H. Detection 
of Ki-ras mutations in tissue and plasma samples of patients 
with pancreatic cancer using PNA-mediated PCR clamping 
and hybridisation probes. Br J Cancer. 2005. https://doi.
org/10.1038/sj.bjc.6602319.
Oncotarget97786www.impactjournals.com/oncotarget
52. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, 
Tsutsumi K, Kato H, Matsubara T, Okada H, Yamamoto K. 
Detection of K-ras gene mutation by liquid biopsy in 
patients with pancreatic cancer: K-ras in blood with 
pancreatic cancer. Cancer. 2015; 121:2271–80. https://doi.
org/10.1002/cncr.29364.
53. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, 
Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, 
Yilmaz M, Holländer NH, Andersen KK, Johansen JS. 
MicroRNA biomarkers in whole blood for detection of 
pancreatic cancer. JAMA. 2014; 311:392–404. https://doi.
org/10.1001/jama.2013.284664.
54. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, 
Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, 
Tsimberridou AM, Huang HJ, Veronese S, Di Nicolantonio FD, 
Pingle S, et al. Mutation-enrichment next-generation 
sequencing for quantitative detection of KRAS mutations 
in urine cell-free DNA from patients with advanced cancers. 
Clin Cancer Res. 2017.
55. McShane LM, Altman DG, Sauerbrei W, Taube SE, 
Gion M, Clark GM, Statistics Subcommittee of the NCI-
EORTC Working Group on Cancer Diagnostics. REporting 
recommendations for tumor MARKer prognostic studies 
(REMARK). Nat Clin Pract Urol. 2005; 2:416–22.
56. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, 
Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, et al. New 
response evaluation criteria in solid tumours: Revised 
RECIST guideline (version 1.1). Eur J Cancer. 2009; 
45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
